Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-10-13Clinical Trial Update: Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) [Phase 4]
A Phase 4 trial (MOTION) evaluating outcomes in patients with pulmonary arterial hypertension not on active treatment has completed, with re…
-
FDA approval · 2017-09-28FDA Approved: UPTRAVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for UPTRAVI (selexipag) from Actelion Pharmaceuticals US, Inc.
-
FDA approval · 2017-09-27FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
FDA approved a supplemental application for LETAIRIS (ambrisentan) by Gilead Sciences, Inc., resulting in changes to the product's labeling …
-
CLINICAL_TRIALS trial_result · 2017-09-12Clinical Trial Update: A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis [Phase 4]
Phase 4 clinical trial update evaluating ambrisentan and tadalafil in pulmonary arterial hypertension associated with systemic sclerosis; st…
-
CLINICAL_TRIALS trial_result · 2017-09-08Clinical Trial Update: Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) [Phase 4]
Phase 4 safety and tolerability study evaluating rapid dose titration of subcutaneous Remodulin in patients with pulmonary arterial hyperten…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-09-05FDA Approved: TRACLEER — Original Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved TRACLEER (bosentan) through its original application filed by Actelion Pharmaceuticals US, Inc. for the treatment of pulmon…
-
FDA label_change · 2017-09-05FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
FDA approved a supplemental application for TRACLEER (bosentan) to update the product label.
-
CLINICAL_TRIALS trial_result · 2017-09-01Clinical Trial Update: Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication [Phase 4]
A Phase 4 clinical trial reports results on transitioning patients from injectable prostacyclin therapy to inhaled prostacyclin therapy for …
-
FDA approval · 2017-08-25FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for OPSUMIT (macitentan) submitted by Actelion Pharmaceuticals US, Inc., effectively updating/ad…
-
FDA approval · 2017-08-17FDA Approved: SILDENAFIL CITRATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for sildenafil citrate filed by Mylan Pharmaceuticals Inc., clearing a pathway for a generic sil…
-
CLINICAL_TRIALS research · 2017-08-16Clinical Trial Update: Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE [Phase 2]
Phase 2 clinical trial assessing bosentan for exercise-induced pulmonary arterial hypertension in patients with congenital heart disease.
-
CLINICAL_TRIALS research · 2017-08-02Clinical Trial Update: Goal Oriented Strategy to Preserve Ejection Fraction Trial [Phase 4]
This entry summarizes a Phase 4 clinical trial in pulmonary arterial hypertension titled 'Goal Oriented Strategy to Preserve Ejection Fracti…
-
CLINICAL_TRIALS research · 2017-08-01Clinical Trial Update: The PAH Disability and Bothersomeness Questionnaire
This document provides a clinical trial update for the PAH Disability and Bothersomeness Questionnaire involving patients with pulmonary art…
-
FDA approval · 2017-07-31FDA Approved: REVATIO — Supplemental Application (PFIZER LABORATORIES DIV PFIZER INC)
The FDA approved a supplemental NDA for REVATIO (sildenafil citrate) from Pfizer Laboratories Div Pfizer Inc, authorizing changes to the pro…
-
FDA label_change · 2017-07-31FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Revatio (sildenafil citrate) by Viatris Specialty LLC, resulting in changes to the product l…
-
FDA approval · 2017-07-31FDA Approved: REVATIO — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for REVATIO (sildenafil citrate) by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2017-07-28Clinical Trial Update: TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) [Phase 4]
Phase 4 trial update on intravenous Remodulin (treprostinil) in Indian PAH patients; study completed with results posted in 2017.
-
FDA approval · 2017-07-21FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) from Gilead Sciences, Inc., indicating an updated/expanded use or lab…
-
FDA approval · 2017-07-21FDA Approved: UPTRAVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for UPTRAVI (selexipag) by Actelion Pharmaceuticals US, Inc., updating labeling as part of the s…
-
CLINICAL_TRIALS trial_result · 2017-07-21Clinical Trial Update: A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 study evaluating aspirin and simvastatin for pulmonary arterial hypertension was terminated, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-07-17Clinical Trial Update: Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography [NA]
A completed clinical trial evaluating non-invasive diagnostics for pulmonary hypertension using dual-energy computed tomography.
-
CLINICAL_TRIALS trial_result · 2017-07-11Clinical Trial Update: Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography [NA]
A completed clinical study from the Medical University of Graz evaluated non-invasive diagnostics of pulmonary arterial hypertension using d…
-
CLINICAL_TRIALS trial_result · 2017-07-07Clinical Trial Update: NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up
A completed clinical trial update on the NIMS implantable pump for pulmonary arterial hypertension, focusing on safety follow-up.
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 trial comparing two dosing regimens of bosentan in children with pulmonary arterial hypertension has completed, and results have b…
-
CLINICAL_TRIALS trial_result · 2017-06-16Clinical Trial Update: Pulmonary Artery Involvement in Takayasu's Arteritis
A clinical trial evaluating pulmonary artery involvement in Takayasu arteritis has completed; no results are described in the provided snipp…